2015-01-30

Using C. elegans for aging research

Heidi A. Tissenbaum
University of Massachusetts Medical School

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/mccb_pubs

Part of the Cell Biology Commons, Cellular and Molecular Physiology Commons, Developmental Biology Commons, Genetics Commons, and the Molecular Genetics Commons

Repository Citation
Tissenbaum HA. (2015). Using C. elegans for aging research. Molecular, Cell and Cancer Biology Publications. https://doi.org/10.1080/07924259.2014.940470. Retrieved from https://escholarship.umassmed.edu/mccb_pubs/41

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Molecular, Cell and Cancer Biology Publications by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Using *C. elegans* for aging research

Heidi A. Tissenbaum*

Program in Gene Function and Expression, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA

(Received 18 March 2014; accepted 2 June 2014)

Over a century ago, the zoologist Emile Maupas first identified the nematode, *Rhabditis elegans*, in the soil in Algiers. Subsequent work and phylogenic studies renamed the species *Caenorhabditis elegans* or more commonly referred to as *C. elegans*; (*Caeno* meaning recent; *rhabditis* meaning rod; *elegans* meaning nice). However, it was not until 1963, when Sydney Brenner, already successful from his work on DNA, RNA, and the genetic code, suggested the future of biological research lay in model organisms. Brenner believed that biological research required a model system that could grow in vast quantities in the lab, were cheap to maintain and had a simple body plan, and he chose the nematode *C. elegans* to fulfill such a role. Since that time, *C. elegans* has emerged as one of the premiere model systems for aging research. This paper reviews some initial identification of mutants with altered lifespan with a focus on genetics and then discusses advantages and disadvantages for using *C. elegans* as a model system to understand human aging. This review focuses on molecular genetics aspects of this model organism.

**Keywords:** *C. elegans*; longevity; aging; insulin/IGF-1; dauer

**Introduction**

In 1974, a little more than a decade after his first thoughts about working on a model organism, Brenner published four manuscripts, including one entitled ‘The genetics of *Caenorhabditis elegans’* (Brenner 1974) and a new field began. In this influential paper (Brenner 1974), Brenner outlined methodology for isolation, complementation, and mapping of worm mutants. Importantly, the publication also included the successful isolation of several hundred mutants affecting behavior and morphology, a discussion of the number of defined genes, and an estimation of mutation frequency. Since that time, many discoveries including dissection of programmed cell death (Coulson et al. 1986; Ellis et al. 1991), the systematic cloning of the genome (Coulson et al. 1986; Crawford 2001), the deciphering of the entire DNA sequence (Consortium 1998), microRNAs (Lee et al. 1993; Reinhart et al. 2000), RNA interference (Fire et al. 1998), and the use of GFP (Chalfie et al. 1994) have been done in *C. elegans* which has led to an expansion in the number of researchers working with *C. elegans*.

*C. elegans* for aging research

For research on aging, early studies in *C. elegans* focused on the feasibility of measuring lifespan and the use of 5-Fluoro-2′-deoxyuridine (FUDR) to maintain synchronous cultures of aged animals (Hosono 1978a, 1978b). In 1977, Klass (1977) published that *C. elegans* was a good system for aging studies as he established a method to consistently measure lifespan, and he concluded that this could lead to future detailed analysis combining genetics and biochemistry. In these early studies, Klass found that altering either temperature or the amount of food resulted in a change in lifespan. In addition, only small effects on lifespan were observed based on parental age or parental lifespan. Klass performed a clonal genetic screen for mutants with altered lifespan and identified five mutants (Klass 1983). Interestingly, later genetic work on these mutants in the laboratory of Tom Johnson, mapped all of them to a single genetic locus, named *age-1* (Friedman & Johnson 1988). This was the first breakthrough in aging research for studies based on *C. elegans* as this study revealed that it was possible to identify mutants that altered lifespan and more importantly, individual genes could modulate lifespan.

From the initial characterization of mutants that altered lifespan, the words lifespan and aging have often been used interchangeably. However, lifespan is a single measureable parameter that defines the amount of time an organism is alive but does not give any indication for how an animal is actually aging. Lifespan as a measurement gives little detail about the health of the animal. For this reason, healthspan, defined as the time that an individual is active, productive and free from age-associated disease, is starting to become the focus of aging research (reviewed in (Tissenbaum 2012)).

*Email: heidi.tissenbaum@umassmed.edu*

© 2014 The Author(s). Published by Taylor & Francis.

This is an Open Access article. Non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly attributed, cited, and is not altered, transformed, or built upon in any way, is permitted. The moral rights of the named author(s) have been asserted.
Equally important for aging research is the use of the term regulation. Is aging regulated? Is lifespan regulated? A regulated process should indicate that this is a trait that would be selected for over time. However, fitness competitions between wild type and daf-2 mutants, show that after four generations, none of the daf-2 mutants remained primarily because of the early fertility defects in the daf-2 mutants (Jenkins et al. 2004). Therefore, similar to other studies with long-lived mutants and consistent with the antagonistic pleiotropy theory of aging (Lakowski & Hekimi 1996; Gems et al. 1998; Chen, Pan et al. 2007; Chen, Senturk et al. 2007; Curran & Ruvkun 2007; Anderson et al. 2011), daf-2 mutants exhibit a heavy fitness cost with lifespan extension (Jenkins et al. 2004). Taken together, lifespan and aging should not be used interchangeably and the use of the word regulation should be monitored (reviewed in (Lithgow 2006; Tissenbaum 2012)).

Several years after the age-1 gene was identified, another gene was shown to modulate lifespan. Similar to mutation in age-1, daf-2 mutants showed adult lifespan extension (Kenyon et al. 1993). Interestingly, previously, both daf-2 and age-1 had showed similarity based on a different phenotype. Under favorable growth conditions, C. elegans develop from an egg through four larval stages (L1-L4) each separated by a molt, and then a final molt into a reproductive self-fertilizing adult hermaphrodite. In response to unfavorable growth conditions, in particular, high levels of a secreted pheromone (i.e. crowding, low food), worms can enter an alternative developmental mode (at the L3 stage) forming dauer larvae (Riddle & Albert 1997). Dauer (German for enduring) larvae (alternate L3) maximize survival until conditions become more favorable, whereupon they will molt and form a reproductive adult. Genetic screens identified mutants affecting the ability to enter this dauer program. These mutants were named daf mutations indicating the dauer formation phenotype. Both daf-2 and age-1 were initially isolated in this type of screen because both daf-2 and age-1 (originally identified as daf-23) mutants show a dauer constitutive (daf-c) phenotype such that even under good growth conditions, mutants will enter the dauer stage (Albert et al. 1981). Genetic epistasis analysis placed these two genes in a similar genetic epistasis pathway for dauer formation that was distinct from the other daf-c mutants (Vowels & Thomas 1992). These studies also revealed that both daf-2 and age-1 mutants could be suppressed by a mutation in the daf-16 gene (Albert et al. 1981; Riddle 1988; Vowels & Thomas 1992; Riddle & Albert 1997). daf-16 (also known as daf-17) was also isolated in these early dauer formation genetic screens because daf-16 mutants show a dauer defective (daf-d) phenotype such that even under poor growth conditions, mutants will not enter the dauer stage (Albert et al. 1981; Riddle 1988; Vowels & Thomas 1992; Riddle & Albert 1997).

Subsequent molecular cloning beginning in 1996, explained why these genes were separate and distinct from other pathways. The genes encoded for members of an insulin/IGF-1 signaling (IIS) pathway where daf-2 encoded for an IIS receptor, age-1 encoded for the catalytic subunit of the PI 3-kinase, and daf-16 encoded for a forkhead box O (FOXO) transcription factor down-stream of the PI 3-kinase signaling cascade. Since then, studies have shown that the IIS pathway is evolutionarily conserved such that mutations in this pathway in flies and mice are also linked to lifespan extension (Barbieri et al. 2003; Yen et al. 2011).

Molecular and genetic studies in Drosophila and C. elegans have identified FOXO as a central regulator of lifespan (Lin et al. 1997; Ogg et al. 1997; Giannakou et al. 2004; Hwangbo et al. 2004). Modulation of Drosophila FOXO (dFoxo) and C. elegans FOXO (daf-16) dosage can either decrease or increase the lifespan of the organism (Lin et al. 1997; Ogg et al. 1997; Giannakou et al. 2004; Hwangbo et al. 2004). Importantly, advances in genomic research have led to new findings in the area of genome-wide association studies in humans. Multiple human population studies have found an association between single nucleotide polymorphisms (SNPs) in human FOXO3 and human lifespan extension (Lunetta et al. 2007; Wilcox et al. 2008; Anselmi et al. 2009; Flachsbart et al. 2009; Li et al. 2009; Soerensen et al. 2010; Zeng et al. 2010; Banasik et al. 2011; Malovini et al. 2011), and the strength of the association appears to increase with age (Flachsbart et al. 2009). Therefore, FOXO3 has emerged as a candidate longevity gene in humans. Taken together, just over a decade from the molecular identification of DAF-16 in C. elegans, multiple studies have linked SNPs associated with human DAF-16/FOXO3 and human lifespan extension.

Dauer and longevity connections

Early studies on dauer larvae showed that dauers were “ageless”; namely once a dauer recovers and develops into a reproductive hermaphrodite, the subsequent adult lifespan (post-dauer) is independent from the time spent as a dauer (Klass & Hirsh 1976). Therefore, it was thought that daf-2 and age-1 were long lived merely due to activation of part of the dauer program manifested in the adult. However, (Kenyon et al. 1993) addressed these concerns by performing lifespan analyses on several other daf-c mutants (later shown to be part of a TGF-β signaling cascade) and found that these mutants did not affect lifespan and the issue seemed resolved. However, approaches including genome- wide microarrays and unbiased LC/MS proteomics have shown that the profiles
of adult long-lived daf-2 mutants are most similar to wild-type dauer larvae (McElwee et al. 2004; McElwee et al. 2006; Depuydt et al. 2014). Moreover, recent studies (Shaw et al. 2007) re-examined the TGF-β daf-2 mutants and found in contrast to earlier studies, these mutants showed lifespan extension. Similarly, recent genetic data revealed that the connections between the IIS pathway and the TGF-β signaling pathway are intertwined to modulate both lifespan and dauer formation (Narasimhan et al. 2011). Taken together, multiple studies suggest that the longevity of daf-2 mutants is due to activation of the dauer program in the adult. Despite the fact that a dauer program, an alternative hibernation state to delay reproduction until growth conditions are favorable, seems worm specific, the signaling pathways that were identified to regulate dauer formation modulate longevity from worms to mice, and are associated with human longevity.

**Advantages of worms**

Why has *C. elegans* been used so successfully for aging research? What would make an organism suitable for aging research? As suggested by Sydney Brenner in 1963, the ability to easily and cheaply grow large quantities of worms in the lab is very helpful for aging research, especially when identifying long-lived mutants. *C. elegans* also have a relatively short lifespan (average approximately 17 days at 20 °C), and the lifespan is largely invariant. The latter allows for identification of mutants that shorten or lengthen average lifespan by a little as 10–15% and still be of statistical significance. Additional benefits of using *C. elegans* include that the entire genome is sequenced and annotated, the availability of an RNAi library comprising approx. 80% of the genes in the genome, the ease of generating transgenic strains and the recent development of gene-targeting approaches. This has allowed for extensive forward and reverse genetic screens for genes that modulate lifespan. The RNAi library allows RNAi to be done by feeding worms bacteria that produce the desired dsRNA and then either the worm or their progeny are scored for a longevity phenotype (Ahringer 2006). Using genome-wide RNAi feeding libraries, the importance of the mitochondria, signal transduction, the response to stress, protein translation, gene expression, and metabolism were found to modulate lifespan (Dillin et al., 2002; Lee et al., 2003; Hamilton et al. 2005; Hansen, Hsu et al. 2005; Hansen, Taubert et al., 2007). Another advantage working with *C. elegans* for studying the aging process is that the lifespan assay is straightforward, which allows for large numbers of worms to be assayed in a single experiment. Therefore, statistical significance can be tested in addition to the analysis of mortality rates. Together, these techniques allow one to comprehensively survey the worm genome for genes that modulate lifespan. This has led to the identification of more than 200 genes and regimens that modulate lifespan in *C. elegans* and revealed evolutionarily conserved pathways that modulate lifespan. Therefore, the combination of the short, invariant lifespan, ease of assays, ample genetic, molecular and genomic tools, and evolutionary conservation has allowed *C. elegans* to develop into a premiere model system for aging research.

**Disadvantages of worms**

Despite all the excellent advantages of working with *C. elegans* for aging research, there are also several disadvantages for *C. elegans* as a model for human aging. First, *C. elegans* have a simple body plan, and lack many defined organs/tissues including a brain, blood, a defined fat cell, internal organs, and is evolutionarily distant from humans. Second, *C. elegans* are also only 1 mm in length which makes biochemistry more difficult. Typically, all biochemistry, microarray, immunoprecipitation, and chromatin immunoprecipitation is performed on whole worm extracts of either mixed-stage animals or animals at a similar growth stage. This may lead to limited understanding of any tissue-specific signaling such as whether a gene is expressed in the hypodermis or the intestine. Finally, *C. elegans* cell culture is limited with no system equivalent to *Drosophila* S2 cells.

**Conclusion**

*C. elegans* has proved to be an invaluable animal for aging research. Thus far, research has focused on the use of lifespan as a measurement of the aging process. These studies have led to the identification of hundreds of genes and regimens that modulate lifespan. Although the initial studies identified genes that altered lifespan and affected dauer diapause, these signaling pathways have nonetheless identified longevity-associated pathways across phylogeny. However, to truly use *C. elegans* for aging research, future studies should focus on understanding the connection between longevity and how an animal ages, with a focus on health. Aging is much more than a lifespan measurement. Aging involves the coordination of multiple systems in an organism and how they change as a function of time. We should strive to use model systems to reveal this systemic coordination on a molecular and genetic level, and how this leads to healthy aging rather than simply lifespan extension.

**Acknowledgements**

I am grateful to Ankita Bansal, Yong-Hak Seo, Micah Belew, and Griffin Walker for advice and discussions. H.A.T. is a William Randolph Hearst Investigator. This project was funded...
in part by grants from the National Institute of Aging (AG02589)
and an endowment from the William Randolph Hearst Foundation.
Due to lack of space, this article focused on molecular genetics and the aging process in Caenorhabditis elegans. For additional
details of the C. elegans aging process see the following reviews
(Ankeny 2001; David 2012; Jung and Sub 2012; McCormick
and Kennedy 2012; Volovik et al. 2014; WormClassroom). For early studies, please refer to Nigon and Dougherty 1949.

References

Ahringer J, editor. 2006. Reverse Genetics in WormBook. (WormBook, ed. The C. elegans Research Community).
Albert PS, Brown SJ, Riddle DL. 1981. Sensory control of dauer larva formation in Caenorhabditis elegans. The Journal of Comparative Neurology. 198:435–451.
Anderson JL, Reynolds RM, Morran LT, Tolman-Thompson J, Phillips PC. 2011. Experimental evolution reveals antagonistic pleiotropy in reproductive timing but not life span in Caenorhabditis elegans. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 66A:1300–1308.
Ankeny RA. 2001. The natural history of Caenorhabditis elegans research. Nature Reviews Genetics. 2:474–479.
Anselmi CV, Malovini A, Roncarati R, Novelli V, Villa F, Condorelli G, Bellazzi R, Puca AA. 2009. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Research. 12:95–104.
Banaski K, Ribel-Madsen R, Gjesing AP, Wegner L, Andersson A, Poulsen P, Borglykke A, Witte DR, Pedersen O, Hansen T, Vaag A. 2011. The FOXO3A rs2802292 G-allele associates with improved peripheral and hepatic insulin sensitivity and increased skeletal muscle-FOXO3A mRNA expression in twins. The Journal of Clinical Endocrinology & Metabolism. 96:E119–E124.
Barbieri M, Bonafe M, Franceschi C, Paolisso G. 2003. Insulin/IGF-1-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. American Journal of Physiology - Endocrinology and Metabolism. 285:E1064–E1071.
Brenner S. 1974. The genetics of Caenorhabditis elegans. Genetics. 77:71–94.
Challie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. 1994. Green fluorescent protein as a marker for gene expression. Science. 263:1423–1425.
Chen D, Pan KZ, Palner JE, Kapahi P. 2007. Longevity determined by developmental arrest genes in Caenorhabditis elegans. Aging Cell. 6:525–533.
Chen J, Senturk D, Wang JI, Muller HG, Carey JR, Caswell H, Caswell-Chen EP. 2007. A demographic analysis of the fitness cost of extended longevity in Caenorhabditis elegans. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 62:126–135.
Coulson A, Sulston J, Brenner S, Karn J. 1986. Toward a physical map of the genome of the nematode Caenorhabditis elegans. Proceedings of the National Academy of Sciences. 83:7821–7825.
Crawford D. 2001. Is life-span the best measure of aging? Science of Aging Knowledge Environment. 2001:wp7.
Curran SP, Ruvkun G. 2007. Lifespan regulation by evolutionarily conserved genes essential for viability. PLoS Genetics. 3:e56.
David DC. 2012. Aging and the aggregating proteome. Frontiers in Genetics. 3:247.
Depuydt G, Xie F, Petyuk VA, Smolders A, Brewer HM, Camp DG 2nd, Smith RD, Braeckman BP. 2014. LC-MS proteomics analysis of the insulin/IGF-1-deficient Caenorhabditis elegans daf-2(e1370) mutant reveals extensive restructuring of intermediary metabolism. Journal of Proteome Research. 13:1938–1956.
Dillin A, Hsu AL, Arantes-Oliveira N, Lehrer-Graiwer J, Hsin H, Fraser AG, Kamath RS, Ahringer J, Kenyon C. 2002. Rates of behavior and aging specified by mitochondrial function during development. Science. 298:2398–2401.
Ellis RE, Jacobson DM, Horvitz HR. 1991. Genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans. Genetics. 129:79–94.
Fatt HV, Dougherty EC. 1963. Genetic control of differential heat tolerance in two strains of the nematode Caenorhabditis elegans. Science. 141:266–267.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, Nikolaus S, Schreiber S, Nebel A. 2009. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proceedings of the National academy of Sciences of the United States of America. 106:2700–2705.
Friedman DB, Johnson TE. 1988. A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics. 118:75–86.
Gems D, Sutton AJ, Sundermeyer ML, Albert PS, King KV, Edgley ML, Larsen PL, Riddle DL. 1998. Two pleiotropic classes of daf-2 mutation affect larval arrest, adult behavior, reproduction and longevity in Caenorhabditis elegans. Genetics. 150:129–155.
Giannakou ME, Goss M, Junger MA, Hafen E, Leevers SJ, Partridge L. 2004. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science. 305:361.
Hamilton B, Dong Y, Shindo M, Liu W, Odell I, Ruvkun G, Lee SS. 2005. A systematic RNAi screen for longevity genes in C. elegans. Genes & Development. 19:1544–1555.
Hansen M, Hsu AL, Dillin A, Kenyon C. 2005. New genes tied to endocrine, metabolic, and dietary regulation of lifespan from a Caenorhabditis elegans genomic RNAi screen. PLoS Genetics. 1:119–128.
Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. 2007. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell. 6:95–110.
Hosono R. 1978a. Age dependent changes in the behavior of Caenorhabditis elegans on attraction to Escherichia coli. Experimental Gerontology. 13:31–36.
Hosono R. 1978b. Sterilization and growth inhibition in Caenorhabditis elegans by 5-fluoro deoxy uridine. Experimental Gerontology. 13:369–374.
Hwangbo DS, Gersham B, Tu MP, Palmer M, Tatar M. 2004. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature. 429:562–566.
Jenkins NL, McCall G, Lithgow GJ. 2004. Fitness cost of extended lifespan in Caenorhabditis elegans. Proceedings of the Royal Society B: Biological Sciences. 271:2523–2526.
Jung HJ, Suh Y. 2012. MicroRNA in aging: from discovery to biology. Current Genomics. 13:548–557.
Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. 1993. A C. elegans mutant that lives twice as long as wild type. Nature. 366:461–464.
Klass M. 1977. Aging in the nematode Caenorhabditis elegans: major biological and environmental factors influencing life span. Mechanisms of Ageing and Development. 6:413–429.

Klass MR. 1983. A method for the isolation of longevity mutants in the nematode Caenorhabditis elegans and initial results. Mechanisms of Ageing and Development. 22:279–286.

Klass MR, Hirsh DI. 1976. Non-ageing developmental variant

Klass M. 1977. Aging in the nematode

Klass MR. 1983. A method for the isolation of longevity mutants in the nematode Caenorhabditis elegans and initial results. Mechanisms of Ageing and Development. 22:279–286.

Lee RC, Feinbaum RL, Ambros V. 1993. The

Li Y, Wang WJ, Cao H, Lu J, Wu C, Hu FY, Guo J, Zhao L, Yang F, Zhang YX, et al. 2009. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Human Molecular Genetics. 18:4897–4904.

Lin K, Dorman JB, Rodan A, Kenyon C. 1997. daf-16: an HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science. 278:1319–1322.

Lithgow GJ. 2006. Why aging isn’t regulated: a lamentation on the use of language in aging literature. Experimental Gerontology. 41:890–893.

Lunetta KL, D’Agostino Sr. RB, Karasik D, Benjamin EJ, Guo CY, Govindaraju R, Kiel DP, Kelly-Hayes M, Massaro JM, Pencina MJ, et al. 2007. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Medical Genetics. 8:513.

Malovini A, Illario M, Iacarino G, Villa F, Ferrario A, Roncarati R, Alselmi CV, Novelli V, Cipolletta S, Leggiero E, Orro A, et al. 2011. Association study on long-living individuals from Southern Italy identifies rs10491334 in the CAMKIV gene that regulates survival proteins. Rejuvenation Research. 14:283–291.

McCormick MA, Kennedy BK. 2012. Genome-scale studies of aging: challenges and opportunities. Current Genomics. 13:500–507.

McElwee JJ, Schuster E, Blanc E, Thornton J, Gems D. 2006. Diapause-associated metabolic traits reiterated in long-liveddaf-2 mutants in the nematode Caenorhabditis elegans. Mechanisms of Ageing and Development. 127:458–472.

McElwee JJ, Schuster E, Blanc E, Thomas JH, Gems D. 2004. Shared transcriptional signature in Caenorhabditis elegans Dauer larvae and long-liveddaf-2 mutants implicates detoxification system in longevity assurance. Journal of Biological Chemistry. 279:44533–44543.

Narasimhan SD, Yen K, Bansal A, Kwon ES, Padmanabhan S, Tissenbaum HA. 2011. PDP-1 links the TGF-beta and IIS pathways to regulate longevity, development, and metabolism. PLoS Genetics. 7:e1001377.

Nigon V, Dougherty EC. 1949. Reproductive patterns and attempts at reciprocal crossing of Rhhabditis elegans Maur, and Rhhabditis briggsae. Doughtery and Nigon. 1949 (Nematoda: Rhhabditidae). Journal of Experimental Zoology. 112:485–503.

Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G. 1997. The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature. 389:994–999.

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Hortviz HR, Ruvkun G. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906.

Riddle DL. 1988. In: Wood WB, editor. The Nematode Caenorhabditis elegans. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY; p. 393–412.

Riddle DL, Albert PS. 1997. Genetic and environmental regulation of Dauer Larva development. In: BT Riddle D, Meyer B, Priess J, editors. C. elegans II. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY; p. 1222.

Shaw WM, Luo S, Lands J, Ashraf J, Murphy CT. 2007. The C. elegans TGF-beta Dauer pathway regulates longevity via insulin signaling. Current Biology. 17:1635–1645.

Soerensen M, et al. 2010. Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. Aging Cell. 9:1010–1017.

The C. elegans Sequence Consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. 1998. Science. 282:2012–2018.

Tissenbaum HA. 2012. Genetics, life span, health span, and the aging process in Caenorhabditis elegans. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 67A:503–510.

Volovik Y, Marques FC, Cohen E. 2014. The nematode Caenorhabditis elegans: a versatile model for the study of proteotoxicity and aging. Methods.

Vowels JJ, Thomas JH. 1992. Genetic analysis of chemoensory control of dauer formation in Caenorhabditis elegans. Genetics. 130:105–123.

Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox DC, Rodriguez B, Curb JD. 2008. FOXO3A genotype is strongly associated with human longevity. Proceedings of the National Academy of Sciences. 105:13987.

WormClassroom. Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison. Available from: http://wormclassroom.org/short-history-c-elegans-research

Yen K, Narasimhan SD, Tissenbaum HA. 2011. DAF-16/Forkhead box O transcription factor: many paths to a single Fork(head) in the road. Antioxidants & Redox Signaling. 14:623–634.

Zeng Y, Cheng L, Chen H, Cao H, Hauser ER, Liu Y, Xiao Z, Tan Q, Tian XL, Vaupel JW. 2010. Effects of FOXO genotypes on longevity: a biodemographic analysis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 65A:1285–1299.